- Market Size (2026)
- USD 44.8 Mn
- Forecast (2036)
- USD 314.3 Mn
- CAGR (2026 to 2036)
- 21.5%
Oncolytic Virus Cancer Therapy Market Size, Market Forecast and Outlook By FMI
Summary of the Oncolytic Virus Cancer Therapy Market
- Demand and Growth Drivers
- Expanding clinical evidence for oncolytic viruses in combination with immune checkpoint inhibitors is creating a structured pathway for adoption in solid tumor indications.
- Regulatory momentum through breakthrough therapy designations and conditional approvals is accelerating market access for genetically engineered viral platforms.
- Rising global cancer incidence and the need for novel treatment modalities beyond checkpoint monotherapy are driving investment in viral oncolysis approaches.
- Product and Segment View
- Solid tumor applications hold 31.2% of the application segment in 2026, supported by clinical evidence in melanoma, glioblastoma, and breast cancer indications.
- Hospitals account for 44.1% of the end-use segment, reflecting specialist infrastructure requirements for viral therapy administration.
- Genetic engineering technology leads at 38.9%, confirming the central role of viral modification in achieving tumor selectivity and immune activation.
- Geography and Competitive Outlook
- South Korea (17.1%) and Japan (16.6%) lead growth, reflecting strong immuno-oncology research infrastructure and clinical trial activity.
- The EU (16.1%) sustains growth through regulatory support for advanced therapy medicinal products and multi-center clinical trials.
- The USA (15.1%) reflects the largest installed base of oncolytic virus therapy use, anchored by T-VEC and expanding pipeline candidates.
- Analyst Opinion
- 'Companies that can demonstrate combination efficacy with checkpoint inhibitors while achieving manufacturing scalability are positioned to capture the highest value in the oncolytic virus therapy market,' says Sabyasachi Ghosh,, Principal Consultant at FMI.
- The oncolytic virus cancer therapy market is transitioning from a single-product category into a multi-platform therapeutic field.
- Adoption is shaped by the accumulation of clinical evidence in combination immunotherapy and the regulatory maturation of advanced biological therapies.
- Growth reflects the persistent unmet need in difficult-to-treat solid tumors and the differentiated mechanism of action offered by viral oncolysis.
- Demand is further supported by expanding manufacturing capabilities and improving viral vector production economics.
Key Takeaways, Market Size, and Forecast
- The oncolytic virus cancer therapy market was valued at USD 36.9 million in 2025.
- The market is set to reach USD 44.8 million by 2026-end and grow at a CAGR of 21.5% between 2026-2036 to reach USD 314.3 million by 2036.
- Herpes simplex virus will dominate with a 22.5% share.
- Solid tumor will lead with a 31.2% share, driven by an expanding clinical trial pipeline for melanoma, glioblastoma, and breast cancer indications where viral oncolysis demonstrates synergistic activity with checkpoint inhibitors.
- By 2036, the oncolytic virus cancer therapy market is expected to be worth USD 314.32 million.
- From 2026 to 2036, the market is projected to expand at a CAGR of 21.5%.
- The market is projected to create an incremental opportunity of USD 269.49 million between 2026 and 2036.
- South Korea (17.1%) and Japan (16.6%) are two of the fastest growing markets in the world.
Oncolytic Virus Cancer Therapy Market Definition
The oncolytic virus cancer therapy market encompasses genetically modified and naturally occurring viruses that selectively infect, replicate within, and destroy cancer cells, including products for solid tumors, hematological malignancies, and various cancer types across hospital, specialty clinic, and research institute settings.
Oncolytic Virus Cancer Therapy Market Inclusions
Market scope encompasses all commercially traded oncolytic virus cancer therapy market products categorized by virus type, application, end use, technology. The range of revenue sizes is from 2026 to 2036.
Oncolytic Virus Cancer Therapy Market Exclusions
The scope does not include products that fall outside the defined segmentation taxonomy, raw materials not processed for end-use applications, or adjacent product categories that do not compete directly within the oncolytic virus cancer therapy market framework.
Oncolytic Virus Cancer Therapy Market Research Methodology
- Primary Research: FMI analysts conducted interviews with industry participants, product manufacturers, distributors, and end-use application specialists across key markets.
- Desk Research: Combined data from industry associations, regulatory bodies, trade publications, and manufacturer disclosures.
- Market sizing and forecasting: Bottom-up methodology aggregating data across segments and regions, with regional adoption curves and cross-validation.
- Data validation: Cross-checked quarterly against global production data and manufacturer-reported information.
Why is the Oncolytic Virus Cancer Therapy Market Growing?
- Expanding clinical evidence for oncolytic viruses in combination with immune checkpoint inhibitors is creating a structured pathway for adoption in solid tumor indications.
- Regulatory momentum through breakthrough therapy designations and conditional approvals is accelerating market access for genetically engineered viral platforms.
- Rising global cancer incidence and the need for novel treatment modalities beyond checkpoint monotherapy are driving investment in viral oncolysis approaches.
The oncolytic virus cancer therapy market reflects a high-growth, pipeline-driven therapeutic category where genetically engineered viruses are demonstrating the ability to selectively destroy cancer cells while stimulating anti-tumor immune responses. Solid tumors account for 31.2% of the application segment, with melanoma, glioblastoma, and breast cancer representing the primary clinical targets. Hospitals lead the end-use segment at 44.1%, reflecting the specialist infrastructure required for viral therapy administration and monitoring.
Herpes simplex virus platforms hold 22.5% of the virus type segment, anchored by Amgen's talimogene laherparepvec (T-VEC), the first FDA-approved oncolytic virus therapy. Genetic engineering technology accounts for 38.9% of the technology segment, reflecting the importance of viral modification for tumor selectivity, immune activation, and safety enhancement.
South Korea (17.1%) and Japan (16.6%) lead country-level growth, reflecting strong immuno-oncology research infrastructure, government support for biological therapies, and clinical trial activity. The market's 21.5% CAGR reflects both the low base and the expanding pipeline of late-stage clinical candidates, with combination approaches alongside PD-1/PD-L1 inhibitors representing the most commercially promising treatment paradigm.
Market Segmentation Analysis
- Solid tumor applications hold 31.2% of the application segment in 2026, supported by clinical evidence in melanoma, glioblastoma, and breast cancer indications.
- Hospitals account for 44.1% of the end-use segment, reflecting specialist infrastructure requirements for viral therapy administration.
- Genetic engineering technology leads at 38.9%, confirming the central role of viral modification in achieving tumor selectivity and immune activation.
The oncolytic virus cancer therapy market is segmented by virus type (herpes simplex virus, adenovirus, vaccinia virus, reovirus, Newcastle disease virus, vesicular stomatitis virus, genetically engineered and wild-type), application (solid tumor, breast cancer, prostate cancer, lung cancer, glioblastoma, melanoma, hematological malignancies), end use (hospitals, specialty clinics, cancer research institutes), and technology (genetic engineering, viral replication enhancement, immune modulation).
Insights into the Solid Tumor Application Segment
In 2026, solid tumor applications are expected to hold 31.2% of the application segment. Oncolytic viruses demonstrate particular promise in difficult-to-treat solid tumors where conventional therapies have limited efficacy. Clinical trials combining viral oncolysis with checkpoint inhibitors are reporting improved response rates in melanoma, glioblastoma, and head and neck cancers, supporting commercial adoption in these indications.
Insights into the Hospital End-Use Segment
Hospitals account for 44.1% of the end-use segment in 2026. Oncolytic virus therapies require specialist oncology infrastructure for intra-tumoral injection, patient monitoring, and immune response assessment. Academic medical centers and comprehensive cancer centers are the primary settings for treatment initiation, with specialty clinics increasingly participating in maintenance protocols.
Oncolytic Virus Cancer Therapy Market Drivers, Restraints, and Opportunities
- Clinical evidence from combination trials with checkpoint inhibitors is creating a structured adoption pathway for oncolytic virus therapies in multiple tumor types.
- Manufacturing complexity and viral vector production scalability represent significant barriers that limit supply capacity and increase therapy costs.
- Regulatory designations including breakthrough therapy and orphan drug status are accelerating development timelines and market access for pipeline candidates.
The oncolytic virus cancer therapy market is expanding rapidly as clinical evidence accumulates, regulatory pathways mature, and combination treatment paradigms demonstrate improved outcomes. Challenges include manufacturing scalability, therapy cost, and the need for specialist administration infrastructure. Opportunities are concentrated in combination immunotherapy, new tumor indications, and next-generation viral engineering platforms.
Combination Immunotherapy Evidence
Demand reflects accumulating clinical data showing that oncolytic viruses enhance the efficacy of PD-1/PD-L1 checkpoint inhibitors by converting immunologically cold tumors into hot tumors. This combination approach is creating a structured commercial pathway in melanoma, head and neck cancer, and other solid tumor indications.
Pipeline Expansion and Regulatory Momentum
Growth reflects the expanding pipeline of genetically engineered oncolytic virus candidates entering late-stage clinical development. Breakthrough therapy designations from the FDA and conditional approvals from the EMA are accelerating development timelines and improving commercial certainty for investors and pharmaceutical partners.
Unmet Need in Difficult-to-Treat Cancers
Adoption is increasing due to the persistent unmet medical need in glioblastoma, pancreatic cancer, and other solid tumors where existing therapies have limited efficacy. Oncolytic viruses offer a differentiated mechanism of action through direct tumor lysis combined with immune system activation.
Analysis of Oncolytic Virus Cancer Therapy Market By Key Countries
.webp "Top Country Growth Comparison Oncolytic Virus Cancer Therapy Market Cagr (2026 2036)")
| Country | CAGR |
|---|---|
| USA | 15.1% |
| UK | 15.6% |
| EU | 16.1% |
| Japan | 16.6% |
| South Korea | 17.1% |
- South Korea (17.1%) and Japan (16.6%) lead growth, reflecting strong immuno-oncology research infrastructure and clinical trial activity.
- The EU (16.1%) sustains growth through regulatory support for advanced therapy medicinal products and multi-center clinical trials.
- The USA (15.1%) reflects the largest installed base of oncolytic virus therapy use, anchored by T-VEC and expanding pipeline candidates.
The global oncolytic virus cancer therapy market is projected to expand at a CAGR of 21.5% from 2026 to 2036. The analysis covers more than 30 countries, and the primary markets are detailed below.
Demand Outlook for Oncolytic Virus Cancer Therapy Market in the United States
The USA is projected to grow at 15.1% through 2036, supported by established T-VEC usage, expanding clinical trials, and strong pharmaceutical investment in viral oncology platforms.
- Established T-VEC usage provides a commercial foundation.
- Expanding clinical trials accelerate pipeline development.
- Pharmaceutical investment drives viral platform development.
Future Outlook for Oncolytic Virus Cancer Therapy Market in the United Kingdom
The UK is projected to grow at 15.6% through 2036, driven by academic research strength, NHS adoption pathways, and multi-center clinical trial participation.
- Academic research institutions drive translational viral oncology.
- NHS adoption pathways support patient access.
- Multi-center trial participation expands clinical evidence.
Opportunity Analysis of Oncolytic Virus Cancer Therapy Market in the EU
The EU is projected to grow at 16.1% through 2036, reflecting EMA regulatory support, manufacturing infrastructure investment, and expanding reimbursement for advanced therapies.
- EMA regulatory framework supports advanced therapy development.
- Manufacturing infrastructure investment improves viral vector supply.
- Reimbursement expansion improves patient access to viral therapies.
In-depth Analysis of Oncolytic Virus Cancer Therapy Market in Japan
Japan is projected to grow at 16.6% through 2036, driven by strong immuno-oncology research, regulatory support for conditional approvals, and clinical adoption in glioblastoma treatment.
- Immuno-oncology research infrastructure drives clinical development.
- Conditional approval pathways accelerate market access.
- Glioblastoma treatment adoption demonstrates clinical utility.
Sales Analysis of Oncolytic Virus Cancer Therapy Market in South Korea
South Korea is projected to grow at 17.1% through 2036, supported by biotech innovation ecosystem, clinical trial infrastructure, and government funding for immuno-oncology research.
- Biotech innovation ecosystem supports viral therapy development.
- Clinical trial infrastructure enables multi-indication studies.
- Government funding accelerates immuno-oncology research programs.
Competitive Landscape and Strategic Positioning
- Amgen Inc. leads with 20.1% market share, anchored by T-VEC (talimogene laherparepvec), the first and only FDA-approved oncolytic virus therapy for melanoma.
- Replimune Group, Oncolytics Biotech, and Transgene SA are advancing late-stage pipeline candidates with differentiated viral platforms and combination approaches.
- Early-stage companies including Vyriad, DNAtrix, and TILT Biotherapeutics are developing next-generation oncolytic viruses with enhanced tumor selectivity and immune activation.
Amgen Inc. leads the market with 20.1% share through T-VEC, the only commercially approved oncolytic virus therapy. The company's clinical expansion into combination protocols with checkpoint inhibitors reinforces its leadership position and generates real-world evidence supporting broader adoption.
Replimune Group is advancing RP1 and RP2, genetically engineered HSV-based oncolytic immunotherapies designed for combination with anti-PD-1 agents. Oncolytics Biotech is developing pelareorep, a reovirus-based therapy targeting solid tumors in combination with checkpoint inhibitors.
Transgene SA is developing TG4050, a personalized oncolytic virus approach using individualized neoantigen identification. TILT Biotherapeutics is pioneering armed oncolytic adenoviruses designed for use with adoptive cell therapy.
Barriers include viral vector manufacturing complexity, clinical trial design challenges for combination therapies, regulatory classification complexity, and the specialist infrastructure required for therapy administration. Strategic priorities include manufacturing scalability, combination clinical evidence generation, and regulatory pathway optimization.
Key Companies in the Oncolytic Virus Cancer Therapy Market
Key global companies leading the oncolytic virus cancer therapy market include:
- Amgen Inc. (USA), Replimune Group Inc. (USA), Oncolytics Biotech Inc. (Canada), Transgene SA (France), Sorrento Therapeutics, Inc. (USA) have strong market infrastructure, established relationships, and broad product portfolios.
- PsiOxus Therapeutics Ltd. (UK), DNAtrix, Inc. (USA), Vyriad, Inc. (USA), TILT Biotherapeutics (Finland) have established positions through specialized capabilities and focused strategies.
- GeneThera Inc. (USA) are among the emerging players developing next-generation approaches.
Competitive Benchmarking: Oncolytic Virus Cancer Therapy Market
| Company | Pipeline Depth | Clinical Evidence | Manufacturing Scale | Regulatory Position |
|---|---|---|---|---|
| Amgen Inc. | High | Very High | Strong | Strong |
| Replimune Group | Very High | Medium | Moderate | Moderate |
| Oncolytics Biotech | High | Medium | Low | Moderate |
| Transgene SA | High | Medium | Moderate | Moderate |
| Sorrento Therapeutics | Medium | Medium | Low | Moderate |
| PsiOxus Therapeutics | High | Medium | Low | Moderate |
| DNAtrix, Inc. | High | Low | Low | Low |
| Vyriad, Inc. | Very High | Low | Low | Low |
| TILT Biotherapeutics | High | Low | Low | Low |
| GeneThera Inc. | Medium | Low | Low | Low |
Source: Future Market Insights competitive analysis, 2026.
Key Developments in Oncolytic Virus Cancer Therapy Market
- In 2025, Amgen Inc. reported expanded clinical use of talimogene laherparepvec (T-VEC) in combination with checkpoint inhibitors for advanced melanoma, demonstrating improved response rates in Phase III trials.
- In 2025, Replimune Group advanced its RP1 oncolytic immunotherapy into pivotal trials for solid tumors, with combination approaches targeting anti-PD-1 resistant cancers.
Key Players in the Oncolytic Virus Cancer Therapy Market
Major Global Players
- Amgen Inc. (USA)
- Replimune Group Inc. (USA)
- Oncolytics Biotech Inc. (Canada)
- Transgene SA (France)
- Sorrento Therapeutics, Inc. (USA)
Emerging Players/Startups
- PsiOxus Therapeutics Ltd. (UK)
- DNAtrix, Inc. (USA)
- Vyriad, Inc. (USA)
- TILT Biotherapeutics (Finland)
- GeneThera Inc. (USA)
Report Scope and Coverage
| Parameter | Details |
|---|---|
| Quantitative Units | USD 44.83 million to USD 314.32 million, at a CAGR of 21.5% |
| Market Definition | The oncolytic virus cancer therapy market encompasses genetically modified and naturally occurring viruses that selectively infect, replicate within, and destroy cancer cells, including products for solid tumors, hematological malignancies, and various cancer types across hospital, specialty clinic, and research institute settings. |
| Regions Covered | North America, Latin America, Europe, East Asia, South Asia and Pacific, Middle East and Africa |
| Countries Covered | USA, UK, France, Germany, Italy, South Korea, Japan, China, India, 30 plus countries |
| Key Companies Profiled | Amgen Inc., Replimune Group Inc., Oncolytics Biotech Inc., Sorrento Therapeutics, Inc., PsiOxus Therapeutics Ltd., DNAtrix, Inc., Vyriad, Inc., Transgene SA, TILT Biotherapeutics, GeneThera Inc. |
| Forecast Period | 2026 to 2036 |
| Approach | Hybrid bottom-up and top-down methodology starting with verified transaction data, projecting adoption velocity across segments and regions. |
Segmentation
Oncolytic Virus Cancer Therapy Market Segmented by Virus Type:
- Herpes Simplex Virus
- Genetically Engineered Oncolytic Viruses
- Adenovirus
- Vaccinia Virus
- Reovirus
- Newcastle Disease Virus
- Vesicular Stomatitis Virus
- Oncolytic Wild-type Viruses
Oncolytic Virus Cancer Therapy Market Segmented by Application:
- Solid Tumor
- Breast Cancer
- Prostate Cancer
- Lung Cancer
- Glioblastoma
- Melanoma
- Hematological Malignancies
- Lymphoma
- Leukemia
- Myeloma
Oncolytic Virus Cancer Therapy Market Segmented by End Use:
- Hospitals
- Specialty Clinics
- Cancer Research Institutes
Oncolytic Virus Cancer Therapy Market Segmented by Technology:
- Genetic Engineering
- Viral Replication Enhancement
- Immune Modulation
Oncolytic Virus Cancer Therapy Market by Region:
- North America
- USA
- Canada
- Mexico
- Latin America
- Brazil
- Chile
- Rest of Latin America
- Western Europe
- Germany
- UK
- Italy
- Spain
- France
- Nordic
- BENELUX
- Rest of Western Europe
- Eastern Europe
- Russia
- Poland
- Hungary
- Balkan & Baltic
- Rest of Eastern Europe
- East Asia
- China
- Japan
- South Korea
- South Asia and Pacific
- India
- ASEAN
- Australia & New Zealand
- Rest of South Asia and Pacific
- Middle East & Africa
- Kingdom of Saudi Arabia
- Other GCC Countries
- Turkiye
- South Africa
- Other African Union
- Rest of Middle East & Africa
Research Sources and Bibliography
- 1. World Health Organization. (2025). WHO Global Cancer Observatory: Cancer Incidence and Treatment Trends. WHO.
- 2. USA Food and Drug Administration. (2025). FDA Biological Product Approvals: Oncolytic Virus Therapeutics. FDA.
- 3. European Medicines Agency. (2024). EMA Advanced Therapy Medicinal Products: Regulatory Framework for Viral Therapies. EMA.
- 4. National Cancer Institute. (2025). NCI Cancer Therapy Evaluation Program: Oncolytic Virus Clinical Trial Data. NCI.
- 5. International Agency for Research on Cancer. (2025). IARC Global Cancer Statistics and Immunotherapy Trends. IARC.
This bibliography is provided for reader reference.
This Report Answers
- Estimating the size of the market and revenue potential from 2026 to 2036.
- Segmentation by virus type, application, end use, and technology.
- Insights about more than 30 markets across key regions.
- Analysis of viral engineering, combination immunotherapy, and manufacturing trends.
- Assessment of the competitive landscape and pipeline positioning.
- Identifying investment opportunities in next-generation viral platforms and combination therapies.
- Tracking regulatory pathway developments and reimbursement expansion.
- Delivery of data in PDF and Excel formats.
Frequently Asked Questions
What is the global market demand for Oncolytic Virus Cancer Therapy in 2026?
In 2026, the global oncolytic virus cancer therapy market is expected to be worth USD 44.83 million.
How big will the Oncolytic Virus Cancer Therapy Market be in 2036?
By 2036, the oncolytic virus cancer therapy market is expected to be worth USD 314.32 million.
How much is demand for Oncolytic Virus Cancer Therapy expected to grow between 2026 and 2036?
Between 2026 and 2036, the demand for oncolytic virus cancer therapy is expected to grow at a CAGR of 21.5%.
Which application segment is expected to lead the market in 2026?
Solid tumor applications are expected to hold 31.2% of the application segment in 2026, supported by clinical evidence in melanoma, glioblastoma, and breast cancer.
What is causing demand to rise in South Korea?
South Korea is projected to grow at 17.1% through 2036, driven by biotech innovation, clinical trial infrastructure, and government immuno-oncology funding.
What is causing demand to rise in Japan?
Japan is projected to grow at 16.6% through 2036, driven by strong immuno-oncology research and clinical adoption in glioblastoma treatment.
What does this report mean by Oncolytic Virus Cancer Therapy Market definition?
The oncolytic virus cancer therapy market encompasses genetically modified and naturally occurring viruses that selectively infect, replicate within, and destroy cancer cells while stimulating anti-tumor immune responses.
How does FMI make the Oncolytic Virus Cancer Therapy forecast and check it?
Forecasting models use a hybrid bottom-up and top-down approach, starting with verified clinical trial data, approved therapy sales, and pipeline probability-of-success estimates, checked against oncology market statistics.
Preview the report firsthand - request a free sample
Get SampleGet the brochure for pricing and purchase details.
Get PDFTable of Content
- Executive Summary
- Global Market Outlook
- Demand-side Trends
- Supply-side Trends
- Technology Roadmap Analysis
- Analysis and Recommendations
- Market Overview
- Market Coverage / Taxonomy
- Market Definition / Scope / Limitations
- Research Methodology
- Chapter Orientation
- Analytical Lens and Working Hypotheses
- Market Structure, Signals, and Trend Drivers
- Benchmarking and Cross-market Comparability
- Market Sizing, Forecasting, and Opportunity Mapping
- Research Design and Evidence Framework
- Desk Research Programme (Secondary Evidence)
- Company Annual and Sustainability Reports
- Peer-reviewed Journals and Academic Literature
- Corporate Websites, Product Literature, and Technical Notes
- Earnings Decks and Investor Briefings
- Statutory Filings and Regulatory Disclosures
- Technical White Papers and Standards Notes
- Trade Journals, Industry Magazines, and Analyst Briefs
- Conference Proceedings, Webinars, and Seminar Materials
- Government Statistics Portals and Public Data Releases
- Press Releases and Reputable Media Coverage
- Specialist Newsletters and Curated Briefings
- Sector Databases and Reference Repositories
- FMI Internal Proprietary Databases and Historical Market Datasets
- Subscription Datasets and Paid Sources
- Social Channels, Communities, and Digital Listening Inputs
- Additional Desk Sources
- Expert Input and Fieldwork (Primary Evidence)
- Primary Modes
- Qualitative Interviews and Expert Elicitation
- Quantitative Surveys and Structured Data Capture
- Blended Approach
- Why Primary Evidence is Used
- Field Techniques
- Interviews
- Surveys
- Focus Groups
- Observational and In-context Research
- Social and Community Interactions
- Stakeholder Universe Engaged
- C-suite Leaders
- Board Members
- Presidents and Vice Presidents
- R&D and Innovation Heads
- Technical Specialists
- Domain Subject-matter Experts
- Scientists
- Physicians and Other Healthcare Professionals
- Governance, Ethics, and Data Stewardship
- Research Ethics
- Data Integrity and Handling
- Primary Modes
- Tooling, Models, and Reference Databases
- Desk Research Programme (Secondary Evidence)
- Data Engineering and Model Build
- Data Acquisition and Ingestion
- Cleaning, Normalisation, and Verification
- Synthesis, Triangulation, and Analysis
- Quality Assurance and Audit Trail
- Market Background
- Market Dynamics
- Drivers
- Restraints
- Opportunity
- Trends
- Scenario Forecast
- Demand in Optimistic Scenario
- Demand in Likely Scenario
- Demand in Conservative Scenario
- Opportunity Map Analysis
- Product Life Cycle Analysis
- Supply Chain Analysis
- Investment Feasibility Matrix
- Value Chain Analysis
- PESTLE and Porter’s Analysis
- Regulatory Landscape
- Regional Parent Market Outlook
- Production and Consumption Statistics
- Import and Export Statistics
- Market Dynamics
- Global Market Analysis 2021 to 2025 and Forecast, 2026 to 2036
- Historical Market Size Value (USD Million) Analysis, 2021 to 2025
- Current and Future Market Size Value (USD Million) Projections, 2026 to 2036
- Y-o-Y Growth Trend Analysis
- Absolute $ Opportunity Analysis
- Global Market Pricing Analysis 2021 to 2025 and Forecast 2026 to 2036
- Global Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Virus Type
- Introduction / Key Findings
- Historical Market Size Value (USD Million) Analysis By Virus Type , 2021 to 2025
- Current and Future Market Size Value (USD Million) Analysis and Forecast By Virus Type , 2026 to 2036
- Herpes Simplex Virus
- Genetically Engineered Oncolytic Viruses
- Adenovirus
- Vaccinia Virus
- Reovirus
- Newcastle Disease Virus
- Vesicular Stomatitis Virus
- Oncolytic Wild-type Viruses
- Herpes Simplex Virus
- Y-o-Y Growth Trend Analysis By Virus Type , 2021 to 2025
- Absolute $ Opportunity Analysis By Virus Type , 2026 to 2036
- Global Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Application
- Introduction / Key Findings
- Historical Market Size Value (USD Million) Analysis By Application, 2021 to 2025
- Current and Future Market Size Value (USD Million) Analysis and Forecast By Application, 2026 to 2036
- Solid Tumor
- Breast Cancer
- Prostate Cancer
- Lung Cancer
- Glioblastoma
- Melanoma
- Hematological Malignancies
- Lymphoma
- Leukemia
- Myeloma
- Solid Tumor
- Y-o-Y Growth Trend Analysis By Application, 2021 to 2025
- Absolute $ Opportunity Analysis By Application, 2026 to 2036
- Global Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By End Use
- Introduction / Key Findings
- Historical Market Size Value (USD Million) Analysis By End Use, 2021 to 2025
- Current and Future Market Size Value (USD Million) Analysis and Forecast By End Use, 2026 to 2036
- Hospitals
- Specialty Clinics
- Cancer Research Institutes
- Hospitals
- Y-o-Y Growth Trend Analysis By End Use, 2021 to 2025
- Absolute $ Opportunity Analysis By End Use, 2026 to 2036
- Global Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Technology
- Introduction / Key Findings
- Historical Market Size Value (USD Million) Analysis By Technology, 2021 to 2025
- Current and Future Market Size Value (USD Million) Analysis and Forecast By Technology, 2026 to 2036
- Genetic Engineering
- Viral Replication Enhancement
- Immune Modulation
- Genetic Engineering
- Y-o-Y Growth Trend Analysis By Technology, 2021 to 2025
- Absolute $ Opportunity Analysis By Technology, 2026 to 2036
- Global Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Region
- Introduction
- Historical Market Size Value (USD Million) Analysis By Region, 2021 to 2025
- Current Market Size Value (USD Million) Analysis and Forecast By Region, 2026 to 2036
- North America
- Latin America
- Western Europe
- Eastern Europe
- East Asia
- South Asia and Pacific
- Middle East & Africa
- Market Attractiveness Analysis By Region
- North America Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Country
- Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
- Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
- By Country
- USA
- Canada
- Mexico
- By Virus Type
- By Application
- By End Use
- By Technology
- By Country
- Market Attractiveness Analysis
- By Country
- By Virus Type
- By Application
- By End Use
- By Technology
- Key Takeaways
- Latin America Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Country
- Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
- Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
- By Country
- Brazil
- Chile
- Rest of Latin America
- By Virus Type
- By Application
- By End Use
- By Technology
- By Country
- Market Attractiveness Analysis
- By Country
- By Virus Type
- By Application
- By End Use
- By Technology
- Key Takeaways
- Western Europe Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Country
- Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
- Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
- By Country
- Germany
- UK
- Italy
- Spain
- France
- Nordic
- BENELUX
- Rest of Western Europe
- By Virus Type
- By Application
- By End Use
- By Technology
- By Country
- Market Attractiveness Analysis
- By Country
- By Virus Type
- By Application
- By End Use
- By Technology
- Key Takeaways
- Eastern Europe Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Country
- Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
- Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
- By Country
- Russia
- Poland
- Hungary
- Balkan & Baltic
- Rest of Eastern Europe
- By Virus Type
- By Application
- By End Use
- By Technology
- By Country
- Market Attractiveness Analysis
- By Country
- By Virus Type
- By Application
- By End Use
- By Technology
- Key Takeaways
- East Asia Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Country
- Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
- Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
- By Country
- China
- Japan
- South Korea
- By Virus Type
- By Application
- By End Use
- By Technology
- By Country
- Market Attractiveness Analysis
- By Country
- By Virus Type
- By Application
- By End Use
- By Technology
- Key Takeaways
- South Asia and Pacific Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Country
- Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
- Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
- By Country
- India
- ASEAN
- Australia & New Zealand
- Rest of South Asia and Pacific
- By Virus Type
- By Application
- By End Use
- By Technology
- By Country
- Market Attractiveness Analysis
- By Country
- By Virus Type
- By Application
- By End Use
- By Technology
- Key Takeaways
- Middle East & Africa Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Country
- Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
- Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
- By Country
- Kingdom of Saudi Arabia
- Other GCC Countries
- Turkiye
- South Africa
- Other African Union
- Rest of Middle East & Africa
- By Virus Type
- By Application
- By End Use
- By Technology
- By Country
- Market Attractiveness Analysis
- By Country
- By Virus Type
- By Application
- By End Use
- By Technology
- Key Takeaways
- Key Countries Market Analysis
- USA
- Pricing Analysis
- Market Share Analysis, 2025
- By Virus Type
- By Application
- By End Use
- By Technology
- Canada
- Pricing Analysis
- Market Share Analysis, 2025
- By Virus Type
- By Application
- By End Use
- By Technology
- Mexico
- Pricing Analysis
- Market Share Analysis, 2025
- By Virus Type
- By Application
- By End Use
- By Technology
- Brazil
- Pricing Analysis
- Market Share Analysis, 2025
- By Virus Type
- By Application
- By End Use
- By Technology
- Chile
- Pricing Analysis
- Market Share Analysis, 2025
- By Virus Type
- By Application
- By End Use
- By Technology
- Germany
- Pricing Analysis
- Market Share Analysis, 2025
- By Virus Type
- By Application
- By End Use
- By Technology
- UK
- Pricing Analysis
- Market Share Analysis, 2025
- By Virus Type
- By Application
- By End Use
- By Technology
- Italy
- Pricing Analysis
- Market Share Analysis, 2025
- By Virus Type
- By Application
- By End Use
- By Technology
- Spain
- Pricing Analysis
- Market Share Analysis, 2025
- By Virus Type
- By Application
- By End Use
- By Technology
- France
- Pricing Analysis
- Market Share Analysis, 2025
- By Virus Type
- By Application
- By End Use
- By Technology
- India
- Pricing Analysis
- Market Share Analysis, 2025
- By Virus Type
- By Application
- By End Use
- By Technology
- ASEAN
- Pricing Analysis
- Market Share Analysis, 2025
- By Virus Type
- By Application
- By End Use
- By Technology
- Australia & New Zealand
- Pricing Analysis
- Market Share Analysis, 2025
- By Virus Type
- By Application
- By End Use
- By Technology
- China
- Pricing Analysis
- Market Share Analysis, 2025
- By Virus Type
- By Application
- By End Use
- By Technology
- Japan
- Pricing Analysis
- Market Share Analysis, 2025
- By Virus Type
- By Application
- By End Use
- By Technology
- South Korea
- Pricing Analysis
- Market Share Analysis, 2025
- By Virus Type
- By Application
- By End Use
- By Technology
- Russia
- Pricing Analysis
- Market Share Analysis, 2025
- By Virus Type
- By Application
- By End Use
- By Technology
- Poland
- Pricing Analysis
- Market Share Analysis, 2025
- By Virus Type
- By Application
- By End Use
- By Technology
- Hungary
- Pricing Analysis
- Market Share Analysis, 2025
- By Virus Type
- By Application
- By End Use
- By Technology
- Kingdom of Saudi Arabia
- Pricing Analysis
- Market Share Analysis, 2025
- By Virus Type
- By Application
- By End Use
- By Technology
- Turkiye
- Pricing Analysis
- Market Share Analysis, 2025
- By Virus Type
- By Application
- By End Use
- By Technology
- South Africa
- Pricing Analysis
- Market Share Analysis, 2025
- By Virus Type
- By Application
- By End Use
- By Technology
- USA
- Market Structure Analysis
- Competition Dashboard
- Competition Benchmarking
- Market Share Analysis of Top Players
- By Regional
- By Virus Type
- By Application
- By End Use
- By Technology
- Competition Analysis
- Competition Deep Dive
- Amgen Inc.
- Overview
- Product Portfolio
- Profitability by Market Segments (Product/Age /Sales Channel/Region)
- Sales Footprint
- Strategy Overview
- Marketing Strategy
- Product Strategy
- Channel Strategy
- Replimune Group Inc.
- Oncolytics Biotech Inc.
- Sorrento Therapeutics, Inc.
- PsiOxus Therapeutics Ltd.
- DNAtrix, Inc.
- Vyriad, Inc.
- Transgene SA
- TILT Biotherapeutics
- GeneThera Inc.
- Other Key Players
- Amgen Inc.
- Competition Deep Dive
- Assumptions & Acronyms Used
